Evidence map›Paper›PMID 36352100›Full record

ArticleCommunications biology2022

Persistent intraocular Ebola virus RNA is associated with severe uveitis in a convalescent rhesus monkey.

Gabriella Worwa, Timothy K Cooper, Steven Yeh, Jessica G Shantha, Amanda M W Hischak, Sarah E Klim, Russell Byrum, Jonathan R Kurtz, Scott M Anthony, Nina M Aiosa and 9 more

Open access · goldAbstract read
In one paragraph

Article in Communications biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Atypical Ebola Virus Disease in a Rhesus Macaque.The Journal of infectious diseases · 2023
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Gabriella WorwaIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Fort Detrick, Frederick, MD, 21702, USA. gabriella.worwa@nih.gov.ORCID 0000-0001-7485-2204
Timothy K CooperIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Fort Detrick, Frederick, MD, 21702, USA.
Steven YehEmory Eye Center, Emory University, Atlanta, GA, 30322, USA.
Jessica G ShanthaEmory Eye Center, Emory University, Atlanta, GA, 30322, USA.
Amanda M W HischakIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Fort Detrick, Frederick, MD, 21702, USA.ORCID 0000-0001-8798-7714
Sarah E KlimIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Fort Detrick, Frederick, MD, 21702, USA.ORCID 0000-0003-0023-028X
Russell ByrumIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Fort Detrick, Frederick, MD, 21702, USA.
Jonathan R KurtzIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Fort Detrick, Frederick, MD, 21702, USA.
Scott M AnthonyIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Fort Detrick, Frederick, MD, 21702, USA.ORCID 0000-0002-1590-7401
Nina M AiosaIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Fort Detrick, Frederick, MD, 21702, USA.
Danny RaglandIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Fort Detrick, Frederick, MD, 21702, USA.
Ji Hyun LeeIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Fort Detrick, Frederick, MD, 21702, USA.ORCID 0000-0003-0450-2879
Marisa St ClaireIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Fort Detrick, Frederick, MD, 21702, USA.ORCID 0000-0001-5493-6187
Carl DavisEmory Vaccine Center, Emory University, Atlanta, GA, 30322, USA.
Rafi AhmedEmory Vaccine Center, Emory University, Atlanta, GA, 30322, USA.
Michael R HolbrookIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Fort Detrick, Frederick, MD, 21702, USA.ORCID 0000-0002-0824-2667
Jens H KuhnIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Fort Detrick, Frederick, MD, 21702, USA.ORCID 0000-0002-7800-6045
Erica Ollmann SaphireCenter for Infectious Disease and Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, 92065, USA.ORCID 0000-0002-1206-7451
Ian CrozierIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Fort Detrick, Frederick, MD, 21702, USA. ian.crozier@nih.gov.ORCID 0000-0003-2485-4011
National Institutes of Health · USEmory University · USFrederick National Laboratory for Cancer Research · USLa Jolla Institute for Immunology · USNebraska Medical Center · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI PENDLETON, RICHARD · 2019 to 2025
$3932.6M
Specific and Broadly Active Monoclonal Antibody Therapeutics Against The FilovirusesU19AI142790 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2019 to 2023
$40.0M
NCI NIH HHS 75N91019D00024NCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INIAID NIH HHS U19 AI142790NIH HHS HHSN272200700016INIH HHS HHSN272201800013CU.S. Department of Health & Human Services | National Institutes of Health (NIH) U19AI142790
6 · The paper itself

Abstract

Despite increasing evidence that uveitis is common and consequential in survivors of Ebola virus disease (EVD), the host-pathogen determinants of the clinical phenotype are undefined, including the pathogenetic role of persistent viral antigen, ocular tissue-specific immune responses, and histopathologic characterization. Absent sampling of human intraocular fluids and tissues, these questions might be investigated in animal models of disease; however, challenges intrinsic to the nonhuman primate model and the animal biosafety level 4 setting have historically limited inquiry. In a rhesus monkey survivor of experimental Ebola virus (EBOV) infection, we observed and documented the clinical, virologic, immunologic, and histopathologic features of severe uveitis. Here we show the clinical natural history, resultant ocular pathology, intraocular antigen-specific antibody detection, and persistent intraocular EBOV RNA detected long after clinical resolution. The association of persistent EBOV RNA as a potential driver of severe immunopathology has pathophysiologic implications for understanding, preventing, and mitigating vision-threatening uveitis in EVD survivors.

Indexed as

EbolavirusHemorrhagic Fever, EbolaUveitisAnimalsHumansMacaca mulattaRNARNA

Identifiers

PMID36352100
PMCPMC9644391
OpenAlexW4308603477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.